专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20020040001A1 Pharmaceutical compositions comprising a soluble laminin receptor precursor or a compound which blocks the interaction of the laminin receptor precursor and PrPSc or PrPc 审中-公开
标题翻译：包含可溶性层粘连蛋白受体前体或阻断层粘连蛋白受体前体与PrPSc或PrPc相互作用的化合物的药物组合物
公开(公告)号：US20020040001A1
公开(公告)日：2002-04-04
申请号：US09964566
申请日：2001-09-28
发明人： Stefan Weiss
IPC分类号： A61K038/17 , G01N033/53
CPC分类号： C07K14/7055 , A01K2217/075 , A61K38/00 , C07K2319/00 , C12N2799/026 , G01N33/6896
摘要： The present invention relates to pharmaceutical compositions comprising a soluble laminin receptor precursor (LRP) or a modification thereof. The present invention also relates to pharmaceutical compositions comprising a compound which blocks the interaction of LRP and PrPSc or PrPc. Said compositions allow the treatment of diseases associated with the presence of PrPSc. In addition, the present invention provides an expression vector for the recombinant production of LRP or any other kind of protein in the baculovirus system.
摘要翻译：本发明涉及包含可溶性层粘连蛋白受体前体（LRP）或其修饰物的药物组合物。本发明还涉及包含阻断LRP与PrPc或PrPc的相互作用的化合物的药物组合物。所述组合物允许治疗与PrPSc存在相关的疾病。此外，本发明提供了在杆状病毒系统中重组生产LRP或任何其他种类的蛋白质的表达载体。

62. 发明授权

US5169930A Fibronectin receptor 失效
标题翻译：纤维蛋白受体
公开(公告)号：US5169930A
公开(公告)日：1992-12-08
申请号：US461349
申请日：1990-01-05
申请人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
发明人： Erkki I. Ruoslahti , Guido Tarone , Filippo G. Giancotti , Bruce E. Vogel
IPC分类号： C07K14/435 , A61K38/00 , C07K1/16 , C07K1/22 , C07K14/705 , C07K16/00 , C07K16/28 , C12N15/02 , C12P21/00 , C12P21/08 , C12R1/91 , G01N33/53
CPC分类号： C07K14/7055 , A61K38/00
摘要： The present invention provides a substantially pure integrin-type receptor characterized in that it consists of an .alpha..sub.v and a .beta..sub.1 subunit. The .alpha..sub.v .beta..sub.1 integrin binds to fibronectin and GRGDSPK but does not bind to vitronectin. The .alpha..sub.v .beta..sub.1 integrin can be used to determine the presence of a .alpha..sub.v .beta..sub.1 ligand and to develop adhesion peptides specific for the various integrins. The presence of the .alpha..sub.v .beta..sub.1 integrin can be used to assess ability of cells to adhere to fibronectin.
摘要翻译：本发明提供了基本上纯的整联蛋白型受体，其特征在于其由αv和β1亚单位组成。 αvβ1整联蛋白与纤连蛋白和GRGDSPK结合，但不结合玻连蛋白。 αvβ1整联蛋白可用于确定αvβ1配体的存在并开发针对各种整合素特异的粘附肽。 αvβ1整联蛋白的存在可用于评估细胞粘附纤连蛋白的能力。

63. 发明公开

US20230201272A1 CELL-BASED THERAPIES AND USES THEREOF 审中-公开
公开(公告)号：US20230201272A1
公开(公告)日：2023-06-29
申请号：US17923652
申请日：2021-05-06
申请人： Tandem Biotherapeutics, Inc.
发明人： Roberto Gramignoli , Stephen Strom
IPC分类号： A61K35/50 , C07K14/705 , A61K9/00
CPC分类号： A61K35/50 , C07K14/70585 , C07K14/70589 , C07K14/7055 , A61K9/0019
摘要： Aspects of the disclosure relate to compositions comprising populations of isolated amniotic cells. In some embodiments, the populations of cells are enriched for human amniotic epithelial cells (hAECs). In some embodiments, the disclosure provides methods of administering the compositions to a subject, for example a subject having certain diseases or disorders such as liver disease, phenylketonuria (PKU), a vocal cord injury or a disease associated with a Complement Factor H deficiency.

64. 发明授权

US09982034B2 Platelet targeted treatment 有权
公开(公告)号：US09982034B2
公开(公告)日：2018-05-29
申请号：US14437457
申请日：2013-10-24
申请人： PLATELET TARGETED THERAPEUTICS, LLC
发明人： David A. Wilcox , Sandra L. Haberichter
IPC分类号： C12N15/85 , C07K14/755 , A61K35/28 , C07K14/705 , A61K48/00 , A61K35/12
CPC分类号： C07K14/755 , A61K35/28 , A61K48/0058 , A61K2035/124 , C07K14/7055
摘要： The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets.

65. 发明申请

US20150344541A1 PLATELET TARGETED TREATMENT 有权
标题翻译：平板针刺治疗
公开(公告)号：US20150344541A1
公开(公告)日：2015-12-03
申请号：US14437457
申请日：2013-10-24
申请人： PLATELET TARGETED THERAPEUTICS, LLC
发明人： David A. Wilcox , Sandra L. Haberichter
IPC分类号： C07K14/755 , A61K35/28
CPC分类号： C07K14/755 , A61K35/28 , A61K48/0058 , A61K2035/124 , C07K14/7055
摘要： The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets.
摘要翻译：本公开内容涉及用于将外源基因的表达靶向血小板的组合物和方法。特别地，本公开涉及通过将外源性试剂（例如凝血因子）的表达靶向血小板来治疗血友病和其他疾病和病症。

66. 发明授权

US07736856B2 Method of screening drug with the use of 67 kDa laminin receptor and drug obtained thereby 失效
标题翻译：使用67kDa层粘连蛋白受体筛选药物的方法和由此获得的药物
公开(公告)号：US07736856B2
公开(公告)日：2010-06-15
申请号：US10551469
申请日：2004-04-01
申请人： Hirofumi Tachibana
发明人： Hirofumi Tachibana
IPC分类号： G01N33/53
CPC分类号： C07K14/7055 , A61K31/353 , G01N33/6896 , G01N2333/7055
摘要： It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, and angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a neuroprotective effect, and anti-allergic effect, and anti-arteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.
摘要翻译：旨在提供使用67kDa层粘连蛋白受体和由此获得的药物筛选药物的新方法。筛选具有抑制细胞增殖，血管发生抑制作用，抑制癌细胞转移的作用，神经保护作用，抗过敏作用，抗动脉硬化作用和/或抑制感染效果的药物的方法其中包括定性或定量测定受试化合物与67kDa层粘连蛋白受体结合度的步骤，并判断该试验化合物是具有抑制细胞增殖作用的药物和抑制血管生成的药物效果，抑制癌细胞转移的作用，神经保护作用和抗过敏作用，以及抗动脉硬化作用和/或抑制Creutzfeldt-Jakob病感染的效果，在通过结果发现的情况下测试化合物与67kDa层粘连蛋白受体结合的测量值和由此获得的药物。

67. 发明授权

US07687464B2 Method for activating T cell protein tyrosine phosphatase for therapeutic applications 失效
标题翻译：激活T细胞蛋白酪氨酸磷酸酶治疗应用的方法
公开(公告)号：US07687464B2
公开(公告)日：2010-03-30
申请号：US11601847
申请日：2006-11-20
申请人： Johanna Ivaska , Elina Mattila
发明人： Johanna Ivaska , Elina Mattila
IPC分类号： A61K38/08 , C07K16/30 , C12Q1/42 , G01N33/574
CPC分类号： C07K14/7055 , A61K38/00 , A61K48/00 , C07K7/06 , C07K2319/03 , C07K2319/10 , C12N15/1137 , C12N2310/14 , C12Y301/03048
摘要： This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase signalling, and a method for preventing cancer, or preventing or inhibiting cancer growth, invasion or metastasis in an individual, based on activating T cell protein tyrosine phosphatase (TCPTP). The invention also concerns pharmaceutical compositions useful in the methods.
摘要翻译：本发明涉及激活T细胞蛋白酪氨酸磷酸酶（TCPTP）和抑制个体中酪氨酸激酶信号转导的方法。本发明涉及一种用于预防或治疗个体中疾病或病症的方法，其中所述疾病或病症可通过抑制酪氨酸激酶信号传导来治愈，以及预防或抑制个体中癌症生长，侵袭或转移的方法，基于活化的T细胞蛋白酪氨酸磷酸酶（TCPTP）。本发明还涉及可用于该方法的药物组合物。

68. 发明申请

US20090185979A1 Integrin Heterodimer and an Alpha Subunit Thereof 审中-公开
标题翻译：整合异源二聚体和阿尔法亚基
公开(公告)号：US20090185979A1
公开(公告)日：2009-07-23
申请号：US12341113
申请日：2008-12-22
申请人： Donald GULLBERG
发明人： Donald GULLBERG
IPC分类号： A61K49/00 , C07K16/18 , G01N33/53 , A61K39/395 , C12N5/06
CPC分类号： C07K16/2839 , C07K14/70546 , C07K14/7055
摘要： A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.
摘要翻译：描述了重组或分离的整合素异二聚体，其包含与亚单位β相关联的新亚基α11。整合素或亚基α11可用作所有类型细胞的标记物或靶标。整合素或其亚基α11可以用作不同生理或治疗方法中的标记物或靶标。它们也可以用作药物组合物和疫苗中的活性成分。

IPRDB

热门服务

关于我们

友情链接

联系方式